Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Prostatic Intraepithelial Neoplasia 1Male Urogenital Diseases 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × Lycopene × Clear all
NCT01882985 2021-01-05

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

University of California, Irvine

Phase 2 Completed
14 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00450749 2019-12-18

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

NCT01443026 2019-11-19

The Effects of Lycopene on High Risk Prostatic Tissue

University of Illinois at Chicago

Phase 2 Completed
66 enrolled 8 charts
Genitourinary

Prostatic Neoplasms, Prostatic Intraepithelial Neoplasia, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡